Lipotoxicity in obesity and diabetes-related cardiac dysfunction

Biochimica et Biophysica Acta - Molecular and Cell Biology of Lipids

Volumn 1861, Issue 10, 2016, Pages 1555-1568

  Zlobine, Igor ^a   Gopal, Keshav ^a,b   Ussher, John R ^a,b  

^a UNIVERSITY OF ALBERTA   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Acylcarnitine; Cardiac lipotoxicity; Cardiomyopathy; Ceramide; Diabetes; Diacylglycerol; Fatty acid metabolism; Lipid intermediates; Obesity; Type 2 diabetes

Indexed keywords

ACYL COENZYME A; ACYLCARNITINE; CERAMIDE; DIACYLGLYCEROL; FATTY ACID; LONG CHAIN FATTY ACID; TRIACYLGLYCEROL; LIPID;

CARDIAC MUSCLE; CARDIOTOXICITY; CONTROLLED CLINICAL TRIAL (TOPIC); DIABETIC CARDIOMYOPATHY; DISEASE ASSOCIATION; FATTY ACID METABOLISM; FATTY ACID OXIDATION; FATTY ACID TRANSPORT; HEART DISEASE; HEART MUSCLE METABOLISM; HEART VENTRICLE FUNCTION; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; LIPID METABOLISM; LIPID STORAGE; LIPOTOXICITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PREVALENCE; PRIORITY JOURNAL; REVIEW; ANIMAL; BIOLOGICAL MODEL; DIABETIC CARDIOMYOPATHIES; METABOLISM; PATHOLOGY;

ANIMALS; DIABETIC CARDIOMYOPATHIES; FATTY ACIDS; HUMANS; LIPIDS; MODELS, BIOLOGICAL; MYOCARDIUM; OBESITY;

EID: 84959180301     PISSN: 13881981     EISSN: 18792618     Source Type: Journal    
DOI: 10.1016/j.bbalip.2016.02.011     Document Type: Review

References (167)

1. [1] American Diabetes, A., Economic costs of diabetes in the U.S. in 2012. Diabetes Care 36 (2013), 1033–1046.
2. [2] Hebert, J.R., Allison, D.B., Archer, E., Lavie, C.J., Blair, S.N., Scientific decision making, policy decisions, and the obesity pandemic. Mayo Clin. Proc. 88 (2013), 593–604.
3. [3] Ginter, E., Simko, V., Type 2 diabetes mellitus, pandemic in 21st century. Adv. Exp. Med. Biol. 771 (2012), 42–50.
4. [4] Qaseem, A., Humphrey, L.L., Sweet, D.E., Starkey, M., Shekelle, P., Oral pharmacologic treatment of type 2 diabetes mellitus: a clinical practice guideline from the American College of Physicians. Ann. Intern. Med. 156 (2012), 218–231.
5. [5] http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2008/ucm116994.htm, in: U.S. Food and Drug Administration (2011) FDA Announces New Recommendations on Evaluating Cardiovascular Risk in Drugs Intended to Treat Type 2 Diabetes., Date Accessed Dec 7 2015.
6. [6] Ussher, J.R., Sutendra, G., Jaswal, J.S., The impact of current and novel anti-diabetic therapies on cardiovascular risk. Futur. Cardiol. 8 (2012), 895–912.
7. [7] Lopaschuk, G.D., Ussher, J.R., Folmes, C.D., Jaswal, J.S., Stanley, W.C., Myocardial fatty acid metabolism in health and disease. Physiol. Rev. 90 (2010), 207–258.
8. [8] Stanley, W.C., Recchia, F.A., Lopaschuk, G.D., Myocardial substrate metabolism in the normal and failing heart. Physiol. Rev. 85 (2005), 1093–1129.
9. [9] Lopaschuk, G.D., Folmes, C.D., Stanley, W.C., Cardiac energy metabolism in obesity. Circ. Res. 101 (2007), 335–347.
10. [10] Ussher, J.R., The role of cardiac lipotoxicity in the pathogenesis of diabetic cardiomyopathy. Expert. Rev. Cardiovasc. Ther. 12 (2014), 345–358.
11. [11] Wende, A.R., Symons, J.D., Abel, E.D., Mechanisms of lipotoxicity in the cardiovascular system. Curr. Hypertens. Rep. 14 (2012), 517–531.
12. [12] Jaswal, J.S., Ussher, J.R., Lopaschuk, G.D., Myocardial fatty acid utilization as a determinant of cardiac efficiency and function. Clin. Lipidol. 4 (2009), 379–389.
13. [13] Brindley, D.N., Kok, B.P., Kienesberger, P.C., Lehner, R., Dyck, J.R., Shedding light on the enigma of myocardial lipotoxicity: the involvement of known and putative regulators of fatty acid storage and mobilization. Am. J. Physiol. Endocrinol. Metab. 298 (2010), E897–E908.
14. [14] Schwenk, R.W., Luiken, J.J., Bonen, A., Glatz, J.F., Regulation of sarcolemmal glucose and fatty acid transporters in cardiac disease. Cardiovasc. Res. 79 (2008), 249–258.
15. [15] Glatz, J.F., Luiken, J.J., Bonen, A., Involvement of membrane-associated proteins in the acute regulation of cellular fatty acid uptake. J. Mol. Neurosci. 16 (2001), 123–132 discussion 151-127.
16. [16] Ibrahimi, A., Abumrad, N.A., Role of CD36 in membrane transport of long-chain fatty acids. Curr. Opin. Clin. Nutr. Metab. Care 5 (2002), 139–145.
17. [17] Grevengoed, T.J., Klett, E.L., Coleman, R.A., Acyl-CoA metabolism and partitioning. Annu. Rev. Nutr. 34 (2014), 1–30.
18. [18] Banke, N.H., Wende, A.R., Leone, T.C., O'Donnell, J.M., Abel, E.D., Kelly, D.P., Lewandowski, E.D., Preferential oxidation of triacylglyceride-derived fatty acids in heart is augmented by the nuclear receptor PPARalpha. Circ. Res. 107 (2010), 233–241.
19. [19] Patton, S., Zulak, I.M., Trams, E.G., Fatty acid metabolism via triglyceride in the salmon heart. J. Mol. Cell. Cardiol. 7 (1975), 857–865.
20. [20] Shipp, J.C., Thomas, J.M., Crevasse, L., Oxidation of carbon-14-labeled endogenous lipids by isolated perfused rat heart. Science 143 (1964), 371–373.
21. [21] Murthy, M.S., Pande, S.V., Mechanism of carnitine acylcarnitine translocase-catalyzed import of acylcarnitines into mitochondria. J. Biol. Chem. 259 (1984), 9082–9089.
22. [22] Murthy, M.S., Pande, S.V., Some differences in the properties of carnitine palmitoyltransferase activities of the mitochondrial outer and inner membranes. Biochem. J. 248 (1987), 727–733.
23. [23] Murthy, M.S., Pande, S.V., Malonyl-CoA binding site and the overt carnitine palmitoyltransferase activity reside on the opposite sides of the outer mitochondrial membrane. Proc. Natl. Acad. Sci. U. S. A. 84 (1987), 378–382.
24. [24] Lopaschuk, G.D., Ussher, J.R., Folmes, C.D., Jaswal, J.S., Stanley, W.C., Myocardial fatty acid metabolism in health and disease. Physiol. Rev. 90 (2010), 207–258.
25. [25] Ussher, J.R., Jaswal, J.S., Lopaschuk, G.D., Pyridine nucleotide regulation of cardiac intermediary metabolism. Circ. Res. 111 (2012), 628–641.
26. [26] McGarry, J.D., Brown, N.F., The mitochondrial carnitine palmitoyltransferase system. From concept to molecular analysis. Eur. J. Biochem. 244 (1997), 1–14.
27. [27] Ussher, J.R., Lopaschuk, G.D., The malonyl CoA axis as a potential target for treating ischaemic heart disease. Cardiovasc. Res. 79 (2008), 259–268.
28. [28] Leone, T.C., Kelly, D.P., Transcriptional control of cardiac fuel metabolism and mitochondrial function. Cold Spring Harb. Symp. Quant. Biol. 76 (2011), 175–182.
29. [29] Madrazo, J.A., Kelly, D.P., The PPAR trio: regulators of myocardial energy metabolism in health and disease. J. Mol. Cell. Cardiol. 44 (2008), 968–975.
30. [30] Finck, B.N., Lehman, J.J., Leone, T.C., Welch, M.J., Bennett, M.J., Kovacs, A., Han, X., Gross, R.W., Kozak, R., Lopaschuk, G.D., Kelly, D.P., The cardiac phenotype induced by PPARalpha overexpression mimics that caused by diabetes mellitus. J. Clin. Invest. 109 (2002), 121–130.
31. [31] Sambandam, N., Morabito, D., Wagg, C., Finck, B.N., Kelly, D.P., Lopaschuk, G.D., Chronic activation of PPARalpha is detrimental to cardiac recovery after ischemia. Am. J. Physiol. Heart Circ. Physiol. 290 (2006), H87–H95.
32. [32] Cheng, L., Ding, G., Qin, Q., Huang, Y., Lewis, W., He, N., Evans, R.M., Schneider, M.D., Brako, F.A., Xiao, Y., Chen, Y.E., Yang, Q., Cardiomyocyte-restricted peroxisome proliferator-activated receptor-delta deletion perturbs myocardial fatty acid oxidation and leads to cardiomyopathy. Nat. Med. 10 (2004), 1245–1250.
33. [33] Arner, P., Langin, D., Lipolysis in lipid turnover, cancer cachexia, and obesity-induced insulin resistance. Trends Endocrinol. Metab. 25 (2014), 255–262.
34. [34] Jocken, J.W., Blaak, E.E., Catecholamine-induced lipolysis in adipose tissue and skeletal muscle in obesity. Physiol. Behav. 94 (2008), 219–230.
35. [35] Langin, D., Adipose tissue lipolysis as a metabolic pathway to define pharmacological strategies against obesity and the metabolic syndrome. Pharmacol. Res. 53 (2006), 482–491.
36. [36] Donnelly, K.L., Smith, C.I., Schwarzenberg, S.J., Jessurun, J., Boldt, M.D., Parks, E.J., Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J. Clin. Invest. 115 (2005), 1343–1351.
37. [37] Petersen, K.F., Dufour, S., Savage, D.B., Bilz, S., Solomon, G., Yonemitsu, S., Cline, G.W., Befroy, D., Zemany, L., Kahn, B.B., Papademetris, X., Rothman, D.L., Shulman, G.I., The role of skeletal muscle insulin resistance in the pathogenesis of the metabolic syndrome. Proc. Natl. Acad. Sci. U. S. A. 104 (2007), 12587–12594.
38. [38] Ouwens, D.M., Diamant, M., Fodor, M., Habets, D.D., Pelsers, M.M., El Hasnaoui, M., Dang, Z.C., van den Brom, C.E., Vlasblom, R., Rietdijk, A., Boer, C., Coort, S.L., Glatz, J.F., Luiken, J.J., Cardiac contractile dysfunction in insulin-resistant rats fed a high-fat diet is associated with elevated CD36-mediated fatty acid uptake and esterification. Diabetologia 50 (2007), 1938–1948.
39. [39] Sung, M.M., Koonen, D.P., Soltys, C.L., Jacobs, R.L., Febbraio, M., Dyck, J.R., Increased CD36 expression in middle-aged mice contributes to obesity-related cardiac hypertrophy in the absence of cardiac dysfunction. J. Mol. Med. 89 (2011), 459–469.
40. [40] Luiken, J.J., Ouwens, D.M., Habets, D.D., van der Zon, G.C., Coumans, W.A., Schwenk, R.W., Bonen, A., Glatz, J.F., Permissive action of protein kinase C-zeta in insulin-induced CD36- and GLUT4 translocation in cardiac myocytes. J. Endocrinol. 201 (2009), 199–209.
41. [41] Savage, D.B., Petersen, K.F., Shulman, G.I., Disordered lipid metabolism and the pathogenesis of insulin resistance. Physiol. Rev. 87 (2007), 507–520.
42. [42] Taegtmeyer, H., McNulty, P., Young, M.E., Adaptation and maladaptation of the heart in diabetes: part I: general concepts. Circulation 105 (2002), 1727–1733.
43. [43] Young, M.E., McNulty, P., Taegtmeyer, H., Adaptation and maladaptation of the heart in diabetes: part II: potential mechanisms. Circulation 105 (2002), 1861–1870.
44. [44] Young, M.E., Guthrie, P.H., Razeghi, P., Leighton, B., Abbasi, S., Patil, S., Youker, K.A., Taegtmeyer, H., Impaired long-chain fatty acid oxidation and contractile dysfunction in the obese Zucker rat heart. Diabetes 51 (2002), 2587–2595.
45. [45] Anderson, E.J., Kypson, A.P., Rodriguez, E., Anderson, C.A., Lehr, E.J., Neufer, P.D., Substrate-specific derangements in mitochondrial metabolism and redox balance in the atrium of the type 2 diabetic human heart. J. Am. Coll. Cardiol. 54 (2009), 1891–1898.
46. [46] Buchanan, J., Mazumder, P.K., Hu, P., Chakrabarti, G., Roberts, M.W., Yun, U.J., Cooksey, R.C., Litwin, S.E., Abel, E.D., Reduced cardiac efficiency and altered substrate metabolism precedes the onset of hyperglycemia and contractile dysfunction in two mouse models of insulin resistance and obesity. Endocrinology 146 (2005), 5341–5349.
47. [47] Sankaralingam, S., Abo Alrob, O., Zhang, L., Jaswal, J.S., Wagg, C.S., Fukushima, A., Padwal, R.S., Johnstone, D.E., Sharma, A.M., Lopaschuk, G.D., Lowering body weight in obese mice with diastolic heart failure improves cardiac insulin sensitivity and function: implications for the obesity paradox. Diabetes 64 (2015), 1643–1657.
48. [48] Ussher, J.R., Koves, T.R., Jaswal, J.S., Zhang, L., Ilkayeva, O., Dyck, J.R., Muoio, D.M., Lopaschuk, G.D., Insulin-stimulated cardiac glucose oxidation is increased in high-fat diet-induced obese mice lacking malonyl CoA decarboxylase. Diabetes 58 (2009), 1766–1775.
49. [49] Wright, J.J., Kim, J., Buchanan, J., Boudina, S., Sena, S., Bakirtzi, K., Ilkun, O., Theobald, H.A., Cooksey, R.C., Kandror, K.V., Abel, E.D., Mechanisms for increased myocardial fatty acid utilization following short-term high-fat feeding. Cardiovasc. Res. 82 (2009), 351–360.
50. [50] Zhang, L., Ussher, J.R., Oka, T., Cadete, V.J., Wagg, C., Lopaschuk, G.D., Cardiac diacylglycerol accumulation in high fat-fed mice is associated with impaired insulin-stimulated glucose oxidation. Cardiovasc. Res. 89 (2011), 148–156.
51. [51] Peterson, L.R., Herrero, P., Schechtman, K.B., Racette, S.B., Waggoner, A.D., Kisrieva-Ware, Z., Dence, C., Klein, S., Marsala, J., Meyer, T., Gropler, R.J., Effect of obesity and insulin resistance on myocardial substrate metabolism and efficiency in young women. Circulation 109 (2004), 2191–2196.
52. [52] Peterson, L.R., Soto, P.F., Herrero, P., Mohammed, B.S., Avidan, M.S., Schechtman, K.B., Dence, C., Gropler, R.J., Impact of gender on the myocardial metabolic response to obesity. JACC Cardiovasc. Imaging 1 (2008), 424–433.
53. [53] Rijzewijk, L.J., van der Meer, R.W., Lamb, H.J., de Jong, H.W., Lubberink, M., Romijn, J.A., Bax, J.J., de Roos, A., Twisk, J.W., Heine, R.J., Lammertsma, A.A., Smit, J.W., Diamant, M., Altered myocardial substrate metabolism and decreased diastolic function in nonischemic human diabetic cardiomyopathy: studies with cardiac positron emission tomography and magnetic resonance imaging. J. Am. Coll. Cardiol. 54 (2009), 1524–1532.
54. [54] Heather, L.C., Cole, M.A., Lygate, C.A., Evans, R.D., Stuckey, D.J., Murray, A.J., Neubauer, S., Clarke, K., Fatty acid transporter levels and palmitate oxidation rate correlate with ejection fraction in the infarcted rat heart. Cardiovasc. Res. 72 (2006), 430–437.
55. [55] Neubauer, S., The failing heart–an engine out of fuel. N. Engl. J. Med. 356 (2007), 1140–1151.
56. [56] Zhang, L., Jaswal, J.S., Ussher, J.R., Sankaralingam, S., Wagg, C., Zaugg, M., Lopaschuk, G.D., Cardiac insulin-resistance and decreased mitochondrial energy production precede the development of systolic heart failure after pressure-overload hypertrophy. Circ. Heart Fail. 6 (2013), 1039–1048.
57. [57] Masoud, W.G., Ussher, J.R., Wang, W., Jaswal, J.S., Wagg, C.S., Dyck, J.R., Lygate, C.A., Neubauer, S., Clanachan, A.S., Lopaschuk, G.D., Failing mouse hearts utilize energy inefficiently and benefit from improved coupling of glycolysis and glucose oxidation. Cardiovasc. Res. 101 (2014), 30–38.
58. [58] Koonen, D.P., Febbraio, M., Bonnet, S., Nagendran, J., Young, M.E., Michelakis, E.D., Dyck, J.R., CD36 expression contributes to age-induced cardiomyopathy in mice. Circulation 116 (2007), 2139–2147.
59. [59] Saddik, M., Lopaschuk, G.D., Myocardial triglyceride turnover and contribution to energy substrate utilization in isolated working rat hearts. J. Biol. Chem. 266 (1991), 8162–8170.
60. [60] Wisneski, J.A., Stanley, W.C., Neese, R.A., Gertz, E.W., Effects of acute hyperglycemia on myocardial glycolytic activity in humans. J. Clin. Invest. 85 (1990), 1648–1656.
61. [61] Bucci, M., Borra, R., Nagren, K., Parkka, J.P., Del Ry, S., Maggio, R., Tuunanen, H., Viljanen, T., Cabiati, M., Rigazio, S., Taittonen, M., Pagotto, U., Parkkola, R., Opie, L.H., Nuutila, P., Knuuti, J., Iozzo, P., Trimetazidine reduces endogenous free fatty acid oxidation and improves myocardial efficiency in obese humans. Cardiovasc. Ther. 30 (2012), 333–341.
62. [62] Lee, Y., Hirose, H., Ohneda, M., Johnson, J.H., McGarry, J.D., Unger, R.H., Beta-cell lipotoxicity in the pathogenesis of non-insulin-dependent diabetes mellitus of obese rats: impairment in adipocyte-beta-cell relationships. Proc. Natl. Acad. Sci. U. S. A. 91 (1994), 10878–10882.
63. [63] Unger, R.H., Lipotoxicity in the pathogenesis of obesity-dependent NIDDM. Genetic and clinical implications. Diabetes 44 (1995), 863–870.
64. [64] Choi, C.S., Savage, D.B., Abu-Elheiga, L., Liu, Z.X., Kim, S., Kulkarni, A., Distefano, A., Hwang, Y.J., Reznick, R.M., Codella, R., Zhang, D., Cline, G.W., Wakil, S.J., Shulman, G.I., Continuous fat oxidation in acetyl-CoA carboxylase 2 knockout mice increases total energy expenditure, reduces fat mass, and improves insulin sensitivity. Proc. Natl. Acad. Sci. U. S. A. 104 (2007), 16480–16485.
65. [65] Holland, W.L., Brozinick, J.T., Wang, L.P., Hawkins, E.D., Sargent, K.M., Liu, Y., Narra, K., Hoehn, K.L., Knotts, T.A., Siesky, A., Nelson, D.H., Karathanasis, S.K., Fontenot, G.K., Birnbaum, M.J., Summers, S.A., Inhibition of ceramide synthesis ameliorates glucocorticoid-, saturated-fat-, and obesity-induced insulin resistance. Cell Metab. 5 (2007), 167–179.
66. [66] Shimabukuro, M., Higa, M., Zhou, Y.T., Wang, M.Y., Newgard, C.B., Unger, R.H., Lipoapoptosis in beta-cells of obese prediabetic fa/fa rats. Role of serine palmitoyltransferase overexpression. J. Biol. Chem. 273 (1998), 32487–32490.
67. [67] Ussher, J.R., Koves, T.R., Cadete, V.J., Zhang, L., Jaswal, J.S., Swyrd, S.J., Lopaschuk, D.G., Proctor, S.D., Keung, W., Muoio, D.M., Lopaschuk, G.D., Inhibition of de novo ceramide synthesis reverses diet-induced insulin resistance and enhances whole-body oxygen consumption. Diabetes 59 (2010), 2453–2464.
68. [68] Drosatos, K., Schulze, P.C., Cardiac lipotoxicity: molecular pathways and therapeutic implications. Curr. Heart Fail. Rep. 10 (2013), 109–121.
69. [69] Muoio, D.M., Neufer, P.D., Lipid-induced mitochondrial stress and insulin action in muscle. Cell Metab. 15 (2012), 595–605.
70. [70] Chiu, H.C., Kovacs, A., Ford, D.A., Hsu, F.F., Garcia, R., Herrero, P., Saffitz, J.E., Schaffer, J.E., A novel mouse model of lipotoxic cardiomyopathy. J. Clin. Invest. 107 (2001), 813–822.
71. [71] Finck, B.N., Han, X., Courtois, M., Aimond, F., Nerbonne, J.M., Kovacs, A., Gross, R.W., Kelly, D.P., A critical role for PPARalpha-mediated lipotoxicity in the pathogenesis of diabetic cardiomyopathy: modulation by dietary fat content. Proc. Natl. Acad. Sci. U. S. A. 100 (2003), 1226–1231.
72. [72] Ussher, J.R., The role of incomplete fatty acid β-oxidation in the development of cardiac insulin resistance. Lopaschuk, G.D., Dhalla, N.S., (eds.) Cardiac Energy Metabolism in Health and Disease, 11, 2014, Springer, New York, 221–234.
73. [73] Paul, A., Chan, L., Bickel, P.E., The PAT family of lipid droplet proteins in heart and vascular cells. Curr. Hypertens. Rep. 10 (2008), 461–466.
74. [74] Kienesberger, P.C., Pulinilkunnil, T., Nagendran, J., Dyck, J.R., Myocardial triacylglycerol metabolism. J. Mol. Cell. Cardiol. 55 (2013), 101–110.
75. [75] Coleman, R.A., Lewin, T.M., Muoio, D.M., Physiological and nutritional regulation of enzymes of triacylglycerol synthesis. Annu. Rev. Nutr. 20 (2000), 77–103.
76. [76] Zimmermann, R., Strauss, J.G., Haemmerle, G., Schoiswohl, G., Birner-Gruenberger, R., Riederer, M., Lass, A., Neuberger, G., Eisenhaber, F., Hermetter, A., Zechner, R., Fat mobilization in adipose tissue is promoted by adipose triglyceride lipase. Science 306 (2004), 1383–1386.
77. [77] Haemmerle, G., Zimmermann, R., Hayn, M., Theussl, C., Waeg, G., Wagner, E., Sattler, W., Magin, T.M., Wagner, E.F., Zechner, R., Hormone-sensitive lipase deficiency in mice causes diglyceride accumulation in adipose tissue, muscle, and testis. J. Biol. Chem. 277 (2002), 4806–4815.
78. [78] Severson, D.L., Hee-Cheong, M., Monoacylglycerol lipase activity in cardiac myocytes. Biochem. Cell Biol. 66 (1988), 1013–1018.
79. [79] Atkinson, L.L., Kozak, R., Kelly, S.E., Onay Besikci, A., Russell, J.C., Lopaschuk, G.D., Potential mechanisms and consequences of cardiac triacylglycerol accumulation in insulin-resistant rats. Am. J. Physiol. Endocrinol. Metab. 284 (2003), E923–E930.
80. [80] Listenberger, L.L., Han, X., Lewis, S.E., Cases, S., Farese, R.V. Jr., Ory, D.S., Schaffer, J.E., Triglyceride accumulation protects against fatty acid-induced lipotoxicity. Proc. Natl. Acad. Sci. U. S. A. 100 (2003), 3077–3082.
81. [81] Liu, L., Shi, X., Bharadwaj, K.G., Ikeda, S., Yamashita, H., Yagyu, H., Schaffer, J.E., Yu, Y.H., Goldberg, I.J., DGAT1 expression increases heart triglyceride content but ameliorates lipotoxicity. J. Biol. Chem. 284 (2009), 36312–36323.
82. [82] Ueno, M., Suzuki, J., Zenimaru, Y., Takahashi, S., Koizumi, T., Noriki, S., Yamaguchi, O., Otsu, K., Shen, W.J., Kraemer, F.B., Miyamori, I., Cardiac overexpression of hormone-sensitive lipase inhibits myocardial steatosis and fibrosis in streptozotocin diabetic mice. Am. J. Physiol. Endocrinol. Metab. 294 (2008), E1109–E1118.
83. [83] Pulinilkunnil, T., Kienesberger, P.C., Nagendran, J., Waller, T.J., Young, M.E., Kershaw, E.E., Korbutt, G., Haemmerle, G., Zechner, R., Dyck, J.R., Myocardial adipose triglyceride lipase overexpression protects diabetic mice from the development of lipotoxic cardiomyopathy. Diabetes 62 (2013), 1464–1477.
84. [84] Haemmerle, G., Moustafa, T., Woelkart, G., Buttner, S., Schmidt, A., van de Weijer, T., Hesselink, M., Jaeger, D., Kienesberger, P.C., Zierler, K., Schreiber, R., Eichmann, T., Kolb, D., Kotzbeck, P., Schweiger, M., Kumari, M., Eder, S., Schoiswohl, G., Wongsiriroj, N., Pollak, N.M., Radner, F.P., Preiss-Landl, K., Kolbe, T., Rulicke, T., Pieske, B., Trauner, M., Lass, A., Zimmermann, R., Hoefler, G., Cinti, S., Kershaw, E.E., Schrauwen, P., Madeo, F., Mayer, B., Zechner, R., ATGL-mediated fat catabolism regulates cardiac mitochondrial function via PPAR-alpha and PGC-1. Nat. Med. 17 (2011), 1076–1085.
85. [85] Kienesberger, P.C., Pulinilkunnil, T., Nagendran, J., Young, M.E., Bogner-Strauss, J.G., Hackl, H., Khadour, R., Heydari, E., Haemmerle, G., Zechner, R., Kershaw, E.E., Dyck, J.R., Early structural and metabolic cardiac remodelling in response to inducible adipose triglyceride lipase ablation. Cardiovasc. Res. 99 (2013), 442–451.
86. [86] Lass, A., Zimmermann, R., Haemmerle, G., Riederer, M., Schoiswohl, G., Schweiger, M., Kienesberger, P., Strauss, J.G., Gorkiewicz, G., Zechner, R., Adipose triglyceride lipase-mediated lipolysis of cellular fat stores is activated by CGI-58 and defective in Chanarin–Dorfman syndrome. Cell Metab. 3 (2006), 309–319.
87. [87] Zierler, K.A., Jaeger, D., Pollak, N.M., Eder, S., Rechberger, G.N., Radner, F.P., Woelkart, G., Kolb, D., Schmidt, A., Kumari, M., Preiss-Landl, K., Pieske, B., Mayer, B., Zimmermann, R., Lass, A., Zechner, R., Haemmerle, G., Functional cardiac lipolysis in mice critically depends on comparative gene identification-58. J. Biol. Chem. 288 (2013), 9892–9904.
88. [88] Inoue, T., Kobayashi, K., Inoguchi, T., Sonoda, N., Maeda, Y., Hirata, E., Fujimura, Y., Miura, D., Hirano, K., Takayanagi, R., Downregulation of adipose triglyceride lipase in the heart aggravates diabetic cardiomyopathy in db/db mice. Biochem. Biophys. Res. Commun. 438 (2013), 224–229.
89. [89] Yang, X., Lu, X., Lombes, M., Rha, G.B., Chi, Y.I., Guerin, T.M., Smart, E.J., Liu, J., The G(0)/G(1) switch gene 2 regulates adipose lipolysis through association with adipose triglyceride lipase. Cell Metab. 11 (2010), 194–205.
90. [90] Heier, C., Radner, F.P., Moustafa, T., Schreiber, R., Grond, S., Eichmann, T.O., Schweiger, M., Schmidt, A., Cerk, I.K., Oberer, M., Theussl, H.C., Wojciechowski, J., Penninger, J.M., Zimmermann, R., Zechner, R., G0/G1 switch gene 2 regulates cardiac lipolysis. J. Biol. Chem. 290 (2015), 26141–26150.
91. [91] Fischer, J., Lefevre, C., Morava, E., Mussini, J.M., Laforet, P., Negre-Salvayre, A., Lathrop, M., Salvayre, R., The gene encoding adipose triglyceride lipase (PNPLA2) is mutated in neutral lipid storage disease with myopathy. Nat. Genet. 39 (2007), 28–30.
92. [92] Li, L.O., Klett, E.L., Coleman, R.A., Acyl-CoA synthesis, lipid metabolism and lipotoxicity. Biochim. Biophys. Acta 1801 (2010), 246–251.
93. [93] Durgan, D.J., Smith, J.K., Hotze, M.A., Egbejimi, O., Cuthbert, K.D., Zaha, V.G., Dyck, J.R., Abel, E.D., Young, M.E., Distinct transcriptional regulation of long-chain acyl-CoA synthetase isoforms and cytosolic thioesterase 1 in the rodent heart by fatty acids and insulin. Am. J. Physiol. Heart Circ. Physiol. 290 (2006), H2480–H2497.
94. [94] Shimomura, I., Tokunaga, K., Jiao, S., Funahashi, T., Keno, Y., Kobatake, T., Kotani, K., Suzuki, H., Yamamoto, T., Tarui, S., et al. Marked enhancement of acyl-CoA synthetase activity and mRNA, paralleled to lipoprotein lipase mRNA, in adipose tissues of Zucker obese rats (fa/fa). Biochim. Biophys. Acta 1124 (1992), 112–118.
95. [95] Robishaw, J.D., Neely, J.R., Coenzyme A metabolism. Am. J. Physiol. 248 (1985), E1–E9.
96. [96] Ellis, J.M., Mentock, S.M., Depetrillo, M.A., Koves, T.R., Sen, S., Watkins, S.M., Muoio, D.M., Cline, G.W., Taegtmeyer, H., Shulman, G.I., Willis, M.S., Coleman, R.A., Mouse cardiac acyl coenzyme a synthetase 1 deficiency impairs fatty acid oxidation and induces cardiac hypertrophy. Mol. Cell. Biol. 31 (2011), 1252–1262.
97. [97] Bikman, B.T., Summers, S.A., Ceramides as modulators of cellular and whole-body metabolism. J. Clin. Invest. 121 (2011), 4222–4230.
98. [98] Chavez, J.A., Summers, S.A., A ceramide-centric view of insulin resistance. Cell Metab. 15 (2012), 585–594.
99. [99] Sawai, H., Hannun, Y.A., Ceramide and sphingomyelinases in the regulation of stress responses. Chem. Phys. Lipids 102 (1999), 141–147.
100. [100] Samokhvalov, V., Zlobine, I., Jamieson, K.L., Jurasz, P., Chen, C., Lee, K.S., Hammock, B.D., Seubert, J.M., PPARdelta signaling mediates the cytotoxicity of DHA in H9c2 cells. Toxicol. Lett. 232 (2014), 10–20.
101. [101] Pickersgill, L., Litherland, G.J., Greenberg, A.S., Walker, M., Yeaman, S.J., Key role for ceramides in mediating insulin resistance in human muscle cells. J. Biol. Chem. 282 (2007), 12583–12589.
102. [102] Xia, J.Y., Holland, W.L., Kusminski, C.M., Sun, K., Sharma, A.X., Pearson, M.J., Sifuentes, A.J., McDonald, J.G., Gordillo, R., Scherer, P.E., Targeted induction of ceramide degradation leads to improved systemic metabolism and reduced hepatic steatosis. Cell Metab. 22 (2015), 266–278.
103. [103] Ledeen, R.W., Wu, G., Nuclear sphingolipids: metabolism and signaling. J. Lipid Res. 49 (2008), 1176–1186.
104. [104] Mullen, T.D., Obeid, L.M., Ceramide and apoptosis: exploring the enigmatic connections between sphingolipid metabolism and programmed cell death. Anti Cancer Agents Med. Chem. 12 (2012), 340–363.
105. [105] Park, T.S., Hu, Y., Noh, H.L., Drosatos, K., Okajima, K., Buchanan, J., Tuinei, J., Homma, S., Jiang, X.C., Abel, E.D., Goldberg, I.J., Ceramide is a cardiotoxin in lipotoxic cardiomyopathy. J. Lipid Res. 49 (2008), 2101–2112.
106. [106] Ussher, J.R., Folmes, C.D., Keung, W., Fillmore, N., Jaswal, J.S., Cadete, V.J., Beker, D.L., Lam, V.H., Zhang, L., Lopaschuk, G.D., Inhibition of serine palmitoyl transferase I reduces cardiac ceramide levels and increases glycolysis rates following diet-induced insulin resistance. PLoS One, 7, 2012, e37703.
107. [107] Russo, S.B., Baicu, C.F., Van Laer, A., Geng, T., Kasiganesan, H., Zile, M.R., Cowart, L.A., Ceramide synthase 5 mediates lipid-induced autophagy and hypertrophy in cardiomyocytes. J. Clin. Invest. 122 (2012), 3919–3930.
108. [108] Chun, L., Junlin, Z., Aimin, W., Niansheng, L., Benmei, C., Minxiang, L., Inhibition of ceramide synthesis reverses endothelial dysfunction and atherosclerosis in streptozotocin-induced diabetic rats. Diabetes Res. Clin. Pract. 93 (2011), 77–85.
109. [109] Zhang, Q.J., Holland, W.L., Wilson, L., Tanner, J.M., Kearns, D., Cahoon, J.M., Pettey, D., Losee, J., Duncan, B., Gale, D., Kowalski, C.A., Deeter, N., Nichols, A., Deesing, M., Arrant, C., Ruan, T., Boehme, C., McCamey, D.R., Rou, J., Ambal, K., Narra, K.K., Summers, S.A., Abel, E.D., Symons, J.D., Ceramide mediates vascular dysfunction in diet-induced obesity by PP2A-mediated dephosphorylation of the eNOS-Akt complex. Diabetes 61 (2012), 1848–1859.
110. [110] Bharath, L.P., Ruan, T., Li, Y., Ravindran, A., Wan, X., Nhan, J.K., Walker, M.L., Deeter, L., Goodrich, R., Johnson, E., Munday, D., Mueller, R., Kunz, D., Jones, D., Reese, V., Summers, S.A., Babu, P.V., Holland, W.L., Zhang, Q.J., Abel, E.D., Symons, J.D., Ceramide-Initiated protein phosphatase 2A activation contributes to arterial dysfunction In vivo. Diabetes 64 (2015), 3914–3926.
111. [111] Lee, S.Y., Kim, J.R., Hu, Y., Khan, R., Kim, S.J., Bharadwaj, K.G., Davidson, M.M., Choi, C.S., Shin, K.O., Lee, Y.M., Park, W.J., Park, I.S., Jiang, X.C., Goldberg, I.J., Park, T.S., Cardiomyocyte specific deficiency of serine palmitoyltransferase subunit 2 reduces ceramide but leads to cardiac dysfunction. J. Biol. Chem. 287 (2012), 18429–18439.
112. [112] Koitabashi, N., Bedja, D., Zaiman, A.L., Pinto, Y.M., Zhang, M., Gabrielson, K.L., Takimoto, E., Kass, D.A., Avoidance of transient cardiomyopathy in cardiomyocyte-targeted tamoxifen-induced MerCreMer gene deletion models. Circ. Res. 105 (2009), 12–15.
113. [113] Baranowski, M., Blachnio-Zabielska, A., Hirnle, T., Harasiuk, D., Matlak, K., Knapp, M., Zabielski, P., Gorski, J., Myocardium of type 2 diabetic and obese patients is characterized by alterations in sphingolipid metabolic enzymes but not by accumulation of ceramide. J. Lipid Res. 51 (2010), 74–80.
114. [114] Jornayvaz, F.R., Shulman, G.I., Diacylglycerol activation of protein kinase cepsilon and hepatic insulin resistance. Cell Metab. 15 (2012), 574–584.
115. [115] Drosatos, K., Bharadwaj, K.G., Lymperopoulos, A., Ikeda, S., Khan, R., Hu, Y., Agarwal, R., Yu, S., Jiang, H., Steinberg, S.F., Blaner, W.S., Koch, W.J., Goldberg, I.J., Cardiomyocyte lipids impair beta-adrenergic receptor function via PKC activation. Am. J. Physiol. Endocrinol. Metab. 300 (2011), E489–E499.
116. [116] Park, M., Wu, D., Park, T., Choi, C.S., Li, R.K., Cheng, K.K., Xu, A., Sweeney, G., APPL1 transgenic mice are protected from high-fat diet-induced cardiac dysfunction. Am. J. Physiol. Endocrinol. Metab. 305 (2013), E795–E804.
117. [117] Chiu, H.C., Kovacs, A., Blanton, R.M., Han, X., Courtois, M., Weinheimer, C.J., Yamada, K.A., Brunet, S., Xu, H., Nerbonne, J.M., Welch, M.J., Fettig, N.M., Sharp, T.L., Sambandam, N., Olson, K.M., Ory, D.S., Schaffer, J.E., Transgenic expression of fatty acid transport protein 1 in the heart causes lipotoxic cardiomyopathy. Circ. Res. 96 (2005), 225–233.
118. [118] Elezaby, A., Sverdlov, A.L., Tu, V.H., Soni, K., Luptak, I., Qin, F., Liesa, M., Shirihai, O.S., Rimer, J., Schaffer, J.E., Wilson, S.C., Edward, J.M., Mitochondrial remodeling in mice with cardiomyocyte-specific lipid overload. J. Mol. Cell. Cardiol. 79 (2015), 275–283.
119. [119] Ali, S., Ussher, J.R., Baggio, L.L., Kabir, M.G., Charron, M.J., Ilkayeva, O., Newgard, C.B., Drucker, D.J., Cardiomyocyte glucagon receptor signaling modulates outcomes in mice with experimental myocardial infarction. Mol. Metab. 4 (2015), 132–143.
120. [120] Su, X., Han, X., Mancuso, D.J., Abendschein, D.R., Gross, R.W., Accumulation of long-chain acylcarnitine and 3-hydroxy acylcarnitine molecular species in diabetic myocardium: identification of alterations in mitochondrial fatty acid processing in diabetic myocardium by shotgun lipidomics. Biochemistry 44 (2005), 5234–5245.
121. [121] Koves, T.R., Ussher, J.R., Noland, R.C., Slentz, D., Mosedale, M., Ilkayeva, O., Bain, J., Stevens, R., Dyck, J.R., Newgard, C.B., Lopaschuk, G.D., Muoio, D.M., Mitochondrial overload and incomplete fatty acid oxidation contribute to skeletal muscle insulin resistance. Cell Metab. 7 (2008), 45–56.
122. [122] Lopaschuk, G.D., Hansen, C.A., Neely, J.R., Fatty acid metabolism in hearts containing elevated levels of CoA. Am. J. Physiol. 250 (1986), H351–H359.
123. [123] Lopaschuk, G.D., Spafford, M.A., Davies, N.J., Wall, S.R., Glucose and palmitate oxidation in isolated working rat hearts reperfused after a period of transient global ischemia. Circ. Res. 66 (1990), 546–553.
124. [124] Lin, H., Su, X., He, B., Protein lysine acylation and cysteine succination by intermediates of energy metabolism. ACS Chem. Biol. 7 (2012), 947–960.
125. [125] Chamberlain, L.H., Shipston, M.J., The physiology of protein S-acylation. Physiol. Rev. 95 (2015), 341–376.
126. [126] Son, N.H., Park, T.S., Yamashita, H., Yokoyama, M., Huggins, L.A., Okajima, K., Homma, S., Szabolcs, M.J., Huang, L.S., Goldberg, I.J., Cardiomyocyte expression of PPARgamma leads to cardiac dysfunction in mice. J. Clin. Invest. 117 (2007), 2791–2801.
127. [127] Son, N.H., Yu, S., Tuinei, J., Arai, K., Hamai, H., Homma, S., Shulman, G.I., Abel, E.D., Goldberg, I.J., PPARgamma-induced cardiolipotoxicity in mice is ameliorated by PPARalpha deficiency despite increases in fatty acid oxidation. J. Clin. Invest. 120 (2010), 3443–3454.
128. [128] Basu, P., Alibhai, F.J., Tsimakouridze, E.V., Singh, R.K., Paglialunga, S., Holloway, G.P., Martino, T.A., Bakovic, M., Male-specific cardiac dysfunction in CTP:phosphoethanolamine cytidylyltransferase (Pcyt2)-deficient mice. Mol. Cell. Biol. 35 (2015), 2641–2657.
129. [129] Lim, H.Y., Bodmer, R., Phospholipid homeostasis and lipotoxic cardiomyopathy: a matter of balance. Fly 5 (2011), 234–236.
130. [130] Lim, H.Y., Wang, W., Wessells, R.J., Ocorr, K., Bodmer, R., Phospholipid homeostasis regulates lipid metabolism and cardiac function through SREBP signaling in Drosophila. Genes Dev. 25 (2011), 189–200.
131. [131] He, Q., Han, X., Cardiolipin remodeling in diabetic heart. Chem. Phys. Lipids 179 (2014), 75–81.
132. [132] Ma, B., Xiong, X., Chen, C., Li, H., Xu, X., Li, X., Li, R., Chen, G., Dackor, R.T., Zeldin, D.C., Wang, D.W., Cardiac-specific overexpression of CYP2J2 attenuates diabetic cardiomyopathy in male streptozotocin-induced diabetic mice. Endocrinology 154 (2013), 2843–2856.
133. [133] Oni-Orisan, A., Alsaleh, N., Lee, C.R., Seubert, J.M., Epoxyeicosatrienoic acids and cardioprotection: the road to translation. J. Mol. Cell. Cardiol. 74 (2014), 199–208.
134. [134] Aasum, E., Khalid, A.M., Gudbrandsen, O.A., How, O.J., Berge, R.K., Larsen, T.S., Fenofibrate modulates cardiac and hepatic metabolism and increases ischemic tolerance in diet-induced obese mice. J. Mol. Cell. Cardiol. 44 (2008), 201–209.
135. [135] Onay-Besikci, A., Altarejos, J.Y., Lopaschuk, G.D., gAd-globular head domain of adiponectin increases fatty acid oxidation in newborn rabbit hearts. J. Biol. Chem. 279 (2004), 44320–44326.
136. [136] Yamauchi, T., Kamon, J., Minokoshi, Y., Ito, Y., Waki, H., Uchida, S., Yamashita, S., Noda, M., Kita, S., Ueki, K., Eto, K., Akanuma, Y., Froguel, P., Foufelle, F., Ferre, P., Carling, D., Kimura, S., Nagai, R., Kahn, B.B., Kadowaki, T., Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat. Med. 8 (2002), 1288–1295.
137. [137] Yoon, M.J., Lee, G.Y., Chung, J.J., Ahn, Y.H., Hong, S.H., Kim, J.B., Adiponectin increases fatty acid oxidation in skeletal muscle cells by sequential activation of AMP-activated protein kinase, p38 mitogen-activated protein kinase, and peroxisome proliferator-activated receptor alpha. Diabetes 55 (2006), 2562–2570.
138. [138] Shetty, S., Kusminski, C.M., Scherer, P.E., Adiponectin in health and disease: evaluation of adiponectin-targeted drug development strategies. Trends Pharmacol. Sci. 30 (2009), 234–239.
139. [139] Mao, X., Kikani, C.K., Riojas, R.A., Langlais, P., Wang, L., Ramos, F.J., Fang, Q., Christ-Roberts, C.Y., Hong, J.Y., Kim, R.Y., Liu, F., Dong, L.Q., APPL1 binds to adiponectin receptors and mediates adiponectin signalling and function. Nat. Cell Biol. 8 (2006), 516–523.
140. [140] Randle, P.J., Regulatory interactions between lipids and carbohydrates: the glucose fatty acid cycle after 35 years. Diabetes Metab. Rev. 14 (1998), 263–283.
141. [141] Randle, P.J., Garland, P.B., Hales, C.N., Newsholme, E.A., The glucose fatty-acid cycle. its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet 1 (1963), 785–789.
142. [142] Jaswal, J.S., Keung, W., Wang, W., Ussher, J.R., Lopaschuk, G.D., Targeting fatty acid and carbohydrate oxidation — a novel therapeutic intervention in the ischemic and failing heart. Biochim. Biophys. Acta 1813 (2011), 1333–1350.
143. [143] Crawford, P.A., Schaffer, J.E., Metabolic stress in the myocardium: adaptations of gene expression. J. Mol. Cell. Cardiol. 55 (2013), 130–138.
144. [144] Boudina, S., Abel, E.D., Mitochondrial uncoupling: a key contributor to reduced cardiac efficiency in diabetes. Physiology 21 (2006), 250–258.
145. [145] McGarry, J.D., Leatherman, G.F., Foster, D.W., Carnitine palmitoyltransferase I. The site of inhibition of hepatic fatty acid oxidation by malonyl-CoA. J. Biol. Chem. 253 (1978), 4128–4136.
146. [146] Sabbah, H.N., Stanley, W.C., Metabolic therapy for heart disease: impact of trimetazidine. Heart Fail. Rev. 10 (2005), 281–288.
147. [147] Ussher, J.R., Lopaschuk, G.D., Clinical implications of energetic problems in cardiovascular disease. Heart Metab. 32 (2006), 9–17.
148. [148] Ussher, J.R., Fillmore, N., Keung, W., Mori, J., Beker, D.L., Wagg, C.S., Jaswal, J.S., Lopaschuk, G.D., Trimetazidine therapy prevents obesity-induced cardiomyopathy in mice. Can. J. Cardiol. 30 (2014), 940–944.
149. [149] Wu, R., Chang, H.C., Khechaduri, A., Chawla, K., Tran, M., Chai, X., Wagg, C., Ghanefar, M., Jiang, X., Bayeva, M., Gonzalez, F., Lopaschuk, G., Ardehali, H., Cardiac-specific ablation of ARNT leads to lipotoxicity and cardiomyopathy. J. Clin. Invest. 124 (2014), 4795–4806.
150. [150] Haemmerle, G., Lass, A., Zimmermann, R., Gorkiewicz, G., Meyer, C., Rozman, J., Heldmaier, G., Maier, R., Theussl, C., Eder, S., Kratky, D., Wagner, E.F., Klingenspor, M., Hoefler, G., Zechner, R., Defective lipolysis and altered energy metabolism in mice lacking adipose triglyceride lipase. Science 312 (2006), 734–737.
151. [151] Kuang, M., Febbraio, M., Wagg, C., Lopaschuk, G.D., Dyck, J.R., Fatty acid translocase/CD36 deficiency does not energetically or functionally compromise hearts before or after ischemia. Circulation 109 (2004), 1550–1557.
152. [152] Nagendran, J., Pulinilkunnil, T., Kienesberger, P.C., Sung, M.M., Fung, D., Febbraio, M., Dyck, J.R., Cardiomyocyte-specific ablation of CD36 improves post-ischemic functional recovery. J. Mol. Cell. Cardiol. 63 (2013), 180–188.
153. [153] Coort, S.L., Hasselbaink, D.M., Koonen, D.P., Willems, J., Coumans, W.A., Chabowski, A., van der Vusse, G.J., Bonen, A., Glatz, J.F., Luiken, J.J., Enhanced sarcolemmal FAT/CD36 content and triacylglycerol storage in cardiac myocytes from obese zucker rats. Diabetes 53 (2004), 1655–1663.
154. [154] Yang, J., Sambandam, N., Han, X., Gross, R.W., Courtois, M., Kovacs, A., Febbraio, M., Finck, B.N., Kelly, D.P., CD36 deficiency rescues lipotoxic cardiomyopathy. Circ. Res. 100 (2007), 1208–1217.
155. [155] Sharma, S., Adrogue, J.V., Golfman, L., Uray, I., Lemm, J., Youker, K., Noon, G.P., Frazier, O.H., Taegtmeyer, H., Intramyocardial lipid accumulation in the failing human heart resembles the lipotoxic rat heart. FASEB J. 18 (2004), 1692–1700.
156. [156] Chokshi, A., Drosatos, K., Cheema, F.H., Ji, R., Khawaja, T., Yu, S., Kato, T., Khan, R., Takayama, H., Knoll, R., Milting, H., Chung, C.S., Jorde, U., Naka, Y., Mancini, D.M., Goldberg, I.J., Schulze, P.C., Ventricular assist device implantation corrects myocardial lipotoxicity, reverses insulin resistance, and normalizes cardiac metabolism in patients with advanced heart failure. Circulation 125 (2012), 2844–2853.
157. [157] McGavock, J.M., Lingvay, I., Zib, I., Tillery, T., Salas, N., Unger, R., Levine, B.D., Raskin, P., Victor, R.G., Szczepaniak, L.S., Cardiac steatosis in diabetes mellitus: a 1H-magnetic resonance spectroscopy study. Circulation 116 (2007), 1170–1175.
158. [158] Nielsen, R., Norrelund, H., Kampmann, U., Kim, W.Y., Ringgaard, S., Schar, M., Moller, N., Botker, H.E., Wiggers, H., Failing heart of patients with type 2 diabetes mellitus can adapt to extreme short-term increases in circulating lipids and does not display features of acute myocardial lipotoxicity. Circ. Heart Fail. 6 (2013), 845–852.
159. [159] Airhart, S., Cade, W.T., Jiang, H., Coggan, A.R., Racette, S.B., Korenblat, K., Spearie, C.A., Waller, S., O'Connor, R., Bashir, A., Ory, D.S., Schaffer, J.E., Novak, E., Farmer, M., Waggoner, A.D., Davila-Roman, V.G., Javidan-Nejad, C., Peterson, L.R., A diet rich in medium-chain fatty acids improves systolic function and alters the lipidomic profile in patients with type 2 diabetes: a pilot study. J. Clin. Endocrinol. Metab., 2015, jc20153292.
160. [160] Tuunanen, H., Engblom, E., Naum, A., Nagren, K., Scheinin, M., Hesse, B., Juhani Airaksinen, K.E., Nuutila, P., Iozzo, P., Ukkonen, H., Opie, L.H., Knuuti, J., Trimetazidine, a metabolic modulator, has cardiac and extracardiac benefits in idiopathic dilated cardiomyopathy. Circulation 118 (2008), 1250–1258.
161. [161] Hait, N.C., Oskeritzian, C.A., Paugh, S.W., Milstien, S., Spiegel, S., Sphingosine kinases, sphingosine 1-phosphate, apoptosis and diseases. Biochim. Biophys. Acta 1758 (2006), 2016–2026.
162. [162] Ali, Z., Ulrik, C.S., Obesity and asthma: a coincidence or a causal relationship? A systematic review. Respir. Med. 107 (2013), 1287–1300.
163. [163] Gallagher, E.J., LeRoith, D., Obesity and diabetes: the increased risk of cancer and cancer-related mortality. Physiol. Rev. 95 (2015), 727–748.
164. [164] Sutherland, E.R., Linking obesity and asthma. Ann. N. Y. Acad. Sci. 1311 (2014), 31–41.
165. [165] Delpy, E., Hatem, S.N., Andrieu, N., de Vaumas, C., Henaff, M., Rucker-Martin, C., Jaffrezou, J.P., Laurent, G., Levade, T., Mercadier, J.J., Doxorubicin induces slow ceramide accumulation and late apoptosis in cultured adult rat ventricular myocytes. Cardiovasc. Res. 43 (1999), 398–407.
166. [166] Mita, M., Tolcher, A.W., Novel apoptosis inducing agents in cancer therapy. Curr. Probl. Cancer 29 (2005), 8–32.
167. [167] Sun, S.Y., Hail, N. Jr., Lotan, R., Apoptosis as a novel target for cancer chemoprevention. J. Natl. Cancer Inst. 96 (2004), 662–672.